In a canine model, a mangostanin-derived PDE4 inhibitor had comparable antifibrotic effects to pirfenidone in a bleomycin-induced rat model of pulmonary fibrosis [35] and did not result in emesis, unlike the nonselective PDE4 inhibitor roflumilast. The gene discussed is PDE4A; the disease is pulmonary fibrosis.